Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Helius Medical Technologies, Inc.

A neurotech company focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Helius Medical Technologies

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS).

PoNS™, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. 

PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

PoNS™ (ponstherapy.com), short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

Studies have shown that individuals with multiple sclerosis who completed 14-weeks of PoNS Therapy® (www.ponstherapy.com) have seen improvements in their gait scores of an average of 8 points. 

An 8-point improvement in your gait can mean improving your walking so you can RSVP “yes” to the wedding, book the vacation you have been putting off, or go for a walk on the beach. 

Learn more at www.ponstherapy.com.

Individual results and experiences may vary. Speak to your physician to determine if PoNS is right for you.

After 14-weeks of PoNS Therapy® (www.ponstherapy.com), 100% of participants with multiple sclerosis saw a 
4-point improvement in dynamic gait index (DGI) scores, with an average of almost 8 points and 40% even saw improvements above 8 points. 

We encourage you to set your sights high – AIM FOR EIGHT points of improvement. 

Learn more: https://lnkd.in/e6Ja8tva

Individual results and experiences may vary. Speak to your physician to determine if PoNS® is right for you. 

#PoNS #PoNSTherapy #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking

PoNS® (www.ponstherapy.com) is committed to improving walking ability across the country.  

Keep an eye out—we hope to bring PoNS to those in the US with gait deficit due to stroke soon.

Learn more: https://lnkd.in/eWPe7Tuy

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Stroke

PoNS® (www.ponstherapy.com) proudly supports our Veterans!

Discover how we're dedicated to helping Veterans with multiple sclerosis improve their gait on our new page. 

Learn more today: https://lnkd.in/eTb9Zfwf

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #GetBackInStepWithLife #PhysicalTherapy #MS #MultipleSclerosis #Veterans #VA #USVeterans #Vet

After using PoNS™ (www.ponstherapy.ca) for 14 weeks, 28% of people with stroke were no longer at fall risk. Routine physical therapy usually only provides a meaningful shift in fall risk for 1-3% of patients. 

Learn more about PoNS Therapy™: www.ponstherapy.ca

Individual results and experiences vary. Patients should talk to their doctor to see if PoNS is right for them. 


#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #TraumaticBrainInjury #TBI #Stroke #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Neurostimulation #FallRisk

	Mar '14	Mar '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue					478K -	1.50M 212.97%	661K 55.82%	522K 21.03%	787K 50.77%	644K 18.17%
cost of revenue		171.78K -				846K -	388K 54.14%	298K 23.20%	463K 55.37%	745K 60.91%
gross profit		-171.78K -			478K -	650K 35.98%	273K 58.00%	224K 17.95%	324K 44.64%	-101K 131.17%
selling and marketing expenses		774.40K -
general and administrative expenses	895.50K -	4.26M 375.88%	5.65M 32.61%	8.47M 49.81%	17.21M 103.33%
selling general and administrative expenses	895.50K -	5.04M 462.36%	5.65M 12.21%	8.47M 49.81%	17.21M 103.33%	16.52M 4.03%	9.71M 41.20%	12.18M 25.34%	10.64M 12.61%	9.23M 13.29%
research and development expenses	171.78K -	3.83M 2,128.87%	4.72M 23.36%	14.39M 204.62%	9.94M 30.92%	8.06M 18.90%	4.58M 43.16%	5.99M 30.73%	4.26M 28.85%	2.94M 30.97%
other expenses					63K -	64K 1.59%	363K 467.19%	200K 44.90%	181K 9.50%
cost and expenses	1.07M -	8.86M 730.58%	10.37M 17.03%	22.85M 120.29%	27.15M 18.82%	25.49M 6.12%	15.05M 40.97%	18.66M 24.04%	15.55M 16.71%	12.91M 16.94%
operating expenses	1.07M -	8.86M 730.58%	10.37M 17.03%	22.85M 120.29%	27.15M 18.82%	24.65M 9.23%	14.66M 40.52%	18.37M 25.29%	15.08M 17.88%	12.17M 19.33%
interest expense		176.49K -	1.67M 843.97%	5.17M 210.38%	1.95M 62.33%				834K -	257K 69.18%
ebitda	-1.07M -	-8.84M 728.70%	-8.60M 2.80%	-17.66M 105.48%	-24.61M 39.29%	-37.92M 54.14%	-14.10M 62.83%	-17.95M 27.35%	-16.09M 10.36%	-12.11M 24.76%
operating income	-1.07M -	-8.86M 730.58%	-10.37M 17.03%	-22.85M 120.29%	-26.68M 16.72%	-24.00M 10.04%	-14.39M 40.05%	-18.14M 26.11%	-14.76M 18.65%	-12.27M 16.87%
depreciation and amortization		20.07K -	1.78M 8,752.25%	17K 99.04%	59K 247.06%	-13.93M 23,708.47%	289K 102.07%	190K 34.26%	-1.33M 801.58%	162K 112.15%
total other income expenses net		126.54K -	-1.78M 1,504.29%	-5.17M 191.00%	-1.95M 62.33%	14.21M 829.72%	256K 98.20%	10K 96.09%	687K 6,770%	3.42M 397.67%
income before tax	-1.07M -	-8.89M 733.38%	-12.04M 35.36%	-28.02M 132.76%	-28.62M 2.14%	-9.78M 65.83%	-14.13M 44.46%	-18.13M 28.32%	-14.07M 22.39%	-8.85M 37.11%
income tax expense		-146.62K -	1.67M 1,236.31%	10.34M 520.77%	3.96M 61.72%	-14.12M 456.66%	-193K 98.63%	-10K 94.82%	-1.51M 15,040%
net income	-1.07M -	-8.89M 733.38%	-12.04M 35.36%	-28.02M 132.76%	-28.62M 2.14%	4.34M 115.16%	-13.94M 421.20%	-18.12M 30.03%	-12.56M 30.70%	-8.85M 29.53%
weighted average shs out	360.59K -	325.99K 9.60%	476.31K 46.11%	532.36K 11.77%	651.02K 22.29%	752.92K 15.65%	1.20M 59.08%	2.46M 105.11%	13.50M 449.38%	607.89K 95.50%
weighted average shs out dil	360.59K -	325.99K 9.60%	476.31K 46.11%	532.36K 11.77%	651.02K 22.29%	752.92K 15.65%	1.20M 59.08%	2.46M 105.11%	13.50M 449.38%	607.89K 95.50%
eps	-2.96 -	-27.29 821.96%	-25.28 7.37%	-52.64 108.23%	-43.97 16.47%	5.76 113.10%	-11.64 302.08%	-7.38 36.60%	-0.93 87.40%	-14.56 1,465.59%
epsdiluted	-2.96 -	-27.29 821.96%	-25.28 7.37%	-52.64 108.23%	-43.97 16.47%	5.76 113.10%	-11.64 302.08%	-7.38 36.60%	-0.93 87.40%	-14.56 1,465.59%

COM:HELIUSMEDICAL

Helius Medical Technologies

Last Close

0.47

21/11 21:00

Market Cap

1.60M

Beta: -

Volume Today

57.45K

Avg: -

Preview